AESTHETICFACTCHECKSCIENCE OVER CLAIMS
Submit a claim
AESTHETICFACTCHECKSCIENCE OVER CLAIMS
Back to current questions

Instagram · Injectables · 30/10/2026

Does permission for a PDGF under-eye trial mean the treatment is approved?

No. Permission to conduct a clinical trial is neither marketing approval nor proof of effectiveness. The study is intended to investigate unanswered questions.

THE CLAIM BEING CHECKED

„Trial permission constitutes marketing approval for PDGF under-eye injections.“

False statement

An editorially formulated question about a current public discussion.

Instagram@newbeautyORIGINAL
Open original post

The @newbeauty post of 29 October 2026 and its linked report of 26 October discuss the announced PDGF trial. The post itself distinguishes clinical research from approval that remains pending; our question explains this distinction. The report relies substantially on the manufacturer founder and a company announcement, not on published efficacy results from this trial. Original content from @newbeauty · Instagram.

THE ANSWER

What is true about it?

No: permission to conduct a clinical trial is not the same as approval to market a treatment for the use being investigated. In the US process described by the FDA, clinical trials generate safety and effectiveness evidence needed for later decisions. Permission for a trial alone therefore establishes neither an effective treatment for under-eye hollows nor a general recommendation to receive it.

See evidence and sources

A CLOSER LOOK

The context behind the claim.

PDGF refers to a growth factor, but a related ingredient name cannot replace evaluation of the particular product, indication and administration route. The historical US REGRANEX document linked here concerns becaplermin gel for certain diabetic ulcers, not cosmetic under-eye injections. It therefore does not demonstrate the effectiveness or safety of those injections or establish their current regulatory status in Germany.

YOUR NEXT STEP

Making a more informed decision.

For any such offer, ask for the product name, administration route and exact approval being claimed for that use. Request published results and distinguish trial announcements from available findings and regulatory marketing decisions. If you are considering trial participation, discuss informed consent, potential risks and alternatives with the responsible study team; advertising cannot replace that conversation.

Where does the question come from?

Current coverage dated 26/10/2026

The @newbeauty post of 29 October 2026 and its linked report of 26 October discuss the announced PDGF trial. The post itself distinguishes clinical research from approval that remains pending; our question explains this distinction. The report relies substantially on the manufacturer founder and a company announcement, not on published efficacy results from this trial.

No reliably published count of accounts reached. Visible likes are interactions, not evidence of a top-reach ranking.

Open the linked social postOriginal post · Editorial fact-check questionThe linked discussion is the reason for this question, not evidence for the medical claim. An educational source is not thereby presented as the author of a myth.

Sources behind the answer.

1
Step 3: Clinical ResearchFDA · Checked: 30/10/2026

Explains clinical research and the US investigational process; trial permission and marketing approval are distinct steps.

2
REGRANEX prescribing informationFDA · Checked: 30/10/2026

Historical 2018 US prescribing document for topical becaplermin in certain diabetic ulcers; not evidence for cosmetic under-eye injections.

Source-based editorial assessment. This is not a personal customer submission or a documented individual specialist approval. It does not replace a personal medical consultation.

THE NEXT QUESTIONCan retinal improve fine lines in photoaged skin?All questions in the archive